Salvage chemotherapy in recurrent or refractory squamous cell cancer of the uterine cervix

David S Alberts, D. J. Garcia

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Squamous cell cancer of the cervix is a relatively drug-resistant tumor. Therefore, chemotherapy is predominately reserved for cervical cancer patients with recurrent or refractory disease following surgery and/or radiation therapy or for patients who present with far advanced, incurable disease. Objective responses to salvage chemotherapy are generally short lived (4 to 6 months) with few patients surviving more than 1 year. Complete clinical remissions primarily occur at extra-pelvic sites (eg, lung, lymph node, and soft tissue metastases). Bulky pelvic tumor in an area of prior irradiation remains largely refractory to further therapy. At present, no chemotherapy regimen has proven superior to single-agent cisplatin, which is associated with an approximately 30% objective response rate. The most effective nonplatinum agents appear to be doxorubicin, ifosfamide, mitolactol, and vincristine. Multiple studies have documented improved partial response rates with platinum-based multiagent chemotherapy, but no regimen has been associated with an improved survival duration. To improve the poor prognosis of this patient group, identification of new agents with at least equivalent activity to cisplatin is mandatory. The development of new platinum-based regimens using currently available agents is unlikely to substantially improve patient survival, although better palliative therapy may result from this approach.

Original languageEnglish (US)
Pages (from-to)37-46
Number of pages10
JournalSeminars in Oncology
Volume21
Issue number4 SUPPL. 7
StatePublished - 1994

Fingerprint

Squamous Cell Neoplasms
Uterine Cervical Neoplasms
Drug Therapy
Platinum
Cisplatin
Mitolactol
Ifosfamide
Social Identification
Survival
Vincristine
Palliative Care
Doxorubicin
Neoplasms
Radiotherapy
Lymph Nodes
Neoplasm Metastasis
Lung
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Salvage chemotherapy in recurrent or refractory squamous cell cancer of the uterine cervix. / Alberts, David S; Garcia, D. J.

In: Seminars in Oncology, Vol. 21, No. 4 SUPPL. 7, 1994, p. 37-46.

Research output: Contribution to journalArticle

@article{308eb139403643bbab8dc77253e736df,
title = "Salvage chemotherapy in recurrent or refractory squamous cell cancer of the uterine cervix",
abstract = "Squamous cell cancer of the cervix is a relatively drug-resistant tumor. Therefore, chemotherapy is predominately reserved for cervical cancer patients with recurrent or refractory disease following surgery and/or radiation therapy or for patients who present with far advanced, incurable disease. Objective responses to salvage chemotherapy are generally short lived (4 to 6 months) with few patients surviving more than 1 year. Complete clinical remissions primarily occur at extra-pelvic sites (eg, lung, lymph node, and soft tissue metastases). Bulky pelvic tumor in an area of prior irradiation remains largely refractory to further therapy. At present, no chemotherapy regimen has proven superior to single-agent cisplatin, which is associated with an approximately 30{\%} objective response rate. The most effective nonplatinum agents appear to be doxorubicin, ifosfamide, mitolactol, and vincristine. Multiple studies have documented improved partial response rates with platinum-based multiagent chemotherapy, but no regimen has been associated with an improved survival duration. To improve the poor prognosis of this patient group, identification of new agents with at least equivalent activity to cisplatin is mandatory. The development of new platinum-based regimens using currently available agents is unlikely to substantially improve patient survival, although better palliative therapy may result from this approach.",
author = "Alberts, {David S} and Garcia, {D. J.}",
year = "1994",
language = "English (US)",
volume = "21",
pages = "37--46",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 7",

}

TY - JOUR

T1 - Salvage chemotherapy in recurrent or refractory squamous cell cancer of the uterine cervix

AU - Alberts, David S

AU - Garcia, D. J.

PY - 1994

Y1 - 1994

N2 - Squamous cell cancer of the cervix is a relatively drug-resistant tumor. Therefore, chemotherapy is predominately reserved for cervical cancer patients with recurrent or refractory disease following surgery and/or radiation therapy or for patients who present with far advanced, incurable disease. Objective responses to salvage chemotherapy are generally short lived (4 to 6 months) with few patients surviving more than 1 year. Complete clinical remissions primarily occur at extra-pelvic sites (eg, lung, lymph node, and soft tissue metastases). Bulky pelvic tumor in an area of prior irradiation remains largely refractory to further therapy. At present, no chemotherapy regimen has proven superior to single-agent cisplatin, which is associated with an approximately 30% objective response rate. The most effective nonplatinum agents appear to be doxorubicin, ifosfamide, mitolactol, and vincristine. Multiple studies have documented improved partial response rates with platinum-based multiagent chemotherapy, but no regimen has been associated with an improved survival duration. To improve the poor prognosis of this patient group, identification of new agents with at least equivalent activity to cisplatin is mandatory. The development of new platinum-based regimens using currently available agents is unlikely to substantially improve patient survival, although better palliative therapy may result from this approach.

AB - Squamous cell cancer of the cervix is a relatively drug-resistant tumor. Therefore, chemotherapy is predominately reserved for cervical cancer patients with recurrent or refractory disease following surgery and/or radiation therapy or for patients who present with far advanced, incurable disease. Objective responses to salvage chemotherapy are generally short lived (4 to 6 months) with few patients surviving more than 1 year. Complete clinical remissions primarily occur at extra-pelvic sites (eg, lung, lymph node, and soft tissue metastases). Bulky pelvic tumor in an area of prior irradiation remains largely refractory to further therapy. At present, no chemotherapy regimen has proven superior to single-agent cisplatin, which is associated with an approximately 30% objective response rate. The most effective nonplatinum agents appear to be doxorubicin, ifosfamide, mitolactol, and vincristine. Multiple studies have documented improved partial response rates with platinum-based multiagent chemotherapy, but no regimen has been associated with an improved survival duration. To improve the poor prognosis of this patient group, identification of new agents with at least equivalent activity to cisplatin is mandatory. The development of new platinum-based regimens using currently available agents is unlikely to substantially improve patient survival, although better palliative therapy may result from this approach.

UR - http://www.scopus.com/inward/record.url?scp=0027941394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027941394&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 37

EP - 46

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 7

ER -